NasdaqCM - Delayed Quote • USD
Affimed N.V. (AFMD)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:48 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -1.67 | -1.39 | -5.18 | -3.75 |
| Low Estimate | -1.91 | -1.6 | -6.51 | -5.33 |
| High Estimate | -1.57 | -0.98 | -3.25 | -2.61 |
| Year Ago EPS | -2.23 | -2.12 | -7.53 | -5.18 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 4 | 5 |
| Avg. Estimate | 1.14M | 950k | 5.58M | 6.5M |
| Low Estimate | 110k | -- | 1.17M | -- |
| High Estimate | 2.21M | 2.21M | 10.62M | 10.94M |
| Year Ago Sales | 5.06M | 1.47M | 8.79M | 5.58M |
| Sales Growth (year/est) | -77.50% | -35.30% | -36.50% | 16.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -2.08 | -2.01 | -1.96 | -1.64 |
| EPS Actual | -2.23 | -2.12 | -1.7 | -1.43 |
| Difference | -0.15 | -0.11 | 0.26 | 0.21 |
| Surprise % | -7.20% | -5.50% | 13.30% | 12.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.67 | -1.39 | -5.18 | -3.75 |
| 7 Days Ago | -1.7 | -1.42 | -5.3 | -3.83 |
| 30 Days Ago | -1.44 | -1.33 | -6.19 | -5.31 |
| 60 Days Ago | -0.14 | -0.13 | -0.61 | -0.53 |
| 90 Days Ago | -0.17 | -0.16 | -0.67 | -0.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 2 | 3 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AFMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.10% | -- | -- | 0.80% |
| Next Qtr. | 34.40% | -- | -- | 9.60% |
| Current Year | 31.20% | -- | -- | 4.50% |
| Next Year | 27.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/25/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/12/2023 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Maintains | Truist Securities: Buy to Buy | 8/11/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/11/2023 |
Related Tickers
PIRS Pieris Pharmaceuticals, Inc.
0.1552
-1.21%
ADAP Adaptimmune Therapeutics plc
0.8984
-8.98%
CTMX CytomX Therapeutics, Inc.
1.7300
-1.70%
CLRB Cellectar Biosciences, Inc.
3.0400
-5.30%
MREO Mereo BioPharma Group plc
2.6500
+2.71%
PRQR ProQR Therapeutics N.V.
1.8600
-2.11%
DSGN Design Therapeutics, Inc.
3.7400
-5.08%
LPTX Leap Therapeutics, Inc.
2.9600
-1.33%
AVIR Atea Pharmaceuticals, Inc.
3.7000
-0.27%
SGMO Sangamo Therapeutics, Inc.
0.4851
-5.99%